Lucius Pharmaceuticals
International business
Evidence / Preclinical

Three models, three questions.

A preclinical index covering global cerebral ischemia, MCAO treatment timing and related limitations.

Conceptual neurovascular scientific plate related to this page
02 / evidence

The model remains visible so the evidence does not sound broader than its source.

Study atlas

Each study answers only the question it can support.

Model, observation and figure stay connected without erasing source boundaries.

Evidence-question ownership map Nine source-mapped records connect by hairlines to three research questions: tissue stress, administration time and brain exposure.source-mapped recordsresearch questionGlobal ischemia modelEdema directionAQP4 directionMCAO model2 / 6 / 24 hWindow narrative0.5 h peak<5% at 6 h1.24× brain / plasma AUCTissue stress3 recordsAdministration time3 recordsBrain exposure3 records
01Global cerebral ischemia: edema and AQP4 direction-of-effectBilateral common carotid artery ligation modelpreclinical / in / vivo02MCAO treatment-window studyMiddle cerebral artery occlusion (MCAO)preclinical / in / vivo
Continue exploring
01Global cerebral ischemia: edema and AQP4.A source-mapped mouse study summary with direction-of-effect visualization and explicit limitations.02MCAO treatment window.A timeline for the source-reported 2 h, 6 h and 24 h treatment-window narrative.03Exposure, shown without false precision.A normalized exposure profile based on source-reported constraints for peak timing, six-hour residual exposure and AUC relationship.04Trace the statement back to its source.The public source register for the current documentation baseline.